Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Business & Regulation Biosimilars, Standards & Regulation

Keeping a Finger on the Biosimilar Pulse

The first approved recombinant DNA-produced biologic drug was human insulin in 1982. Since then, the global biopharmaceutical market has grown to an estimated $163 billion (Dec 2014) (1), a significant proportion of which is made up of monoclonal antibody (mAb) products. In the EU and US, there are over 30 novel approved therapeutic mAbs, with many more currently going through the application process. The market for these products is forecast to reach nearly $58 billion by 2016 and includes best sellers such as Avastin, Herceptin, Humira, Remicade and Rituxin, which account for over half of all global revenues.

Read the full article now

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Fiona Greer

Fiona Greer is Life Sciences Global Director, Biopharma Services Development at SGS.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register